Trials / Not Yet Recruiting
Not Yet RecruitingNCT07014254
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
Therapeutic Study of 177Lu-CTR-FAPI-targeted Nuclear Drugs in Advanced Metastatic Digestive Malignancies
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This was a single-centre, single-arm, non-blinded, prospective study using 20 patients with advanced metastatic GI malignancies recruited to treat patients with advanced metastatic GI malignancies with 177Lu-CTR-FAPI to assess the safety of 177Lu-CTR-FAPI in advanced metastatic GI malignancies; this included radiation therapy dosimetry and initial treatment Determination of Effectiveness
Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Adenocarcinoma of the Stomach
- Colorectal Cancer Metastatic
- Neuroendocrine Tumor (NET)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 177Lu-CTR-FAPI nuclide-targeted therapy | Fasting, special diets, or other specific preparations are not required on the day of 177Lu-CTR-FAPI administration. Patients were given 4 mg ondansetron 30 minutes before treatment to prevent nausea and vomiting. The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi) was diluted with 100 mL of 0.9% saline and given slowly by intravenous infusion over 20-30 minutes (flow rate 200 ml/h). Symptoms and vital signs were monitored before and after treatment. The treatment regimen was planned for a maximum of 3 courses of treatment, with 4-8 weeks between each cycle |
Timeline
- Start date
- 2025-06-20
- Primary completion
- 2028-04-30
- Completion
- 2028-04-30
- First posted
- 2025-06-10
- Last updated
- 2025-06-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07014254. Inclusion in this directory is not an endorsement.